Ginkgo Bioworks Holdings, Inc. (DNA): Price and Financial Metrics

Ginkgo Bioworks Holdings, Inc. (DNA): $1.85

0.01 (+0.54%)

POWR Rating

Component Grades













Add DNA to Watchlist
Sign Up

Industry: Biotech



in industry


  • DNA scores best on the Growth dimension, with a Growth rank ahead of 46.37% of US stocks.
  • The strongest trend for DNA is in Growth, which has been heading down over the past 179 days.
  • DNA ranks lowest in Stability; there it ranks in the 0th percentile.

DNA Stock Summary

  • With a year-over-year growth in debt of 267.85%, GINKGO BIOWORKS HOLDINGS INC's debt growth rate surpasses 94.22% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, GINKGO BIOWORKS HOLDINGS INC is reporting a growth rate of 1,436.93%; that's higher than 98.61% of US stocks.
  • Revenue growth over the past 12 months for GINKGO BIOWORKS HOLDINGS INC comes in at 219.28%, a number that bests 96.08% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to GINKGO BIOWORKS HOLDINGS INC are ENFN, EXPO, TWKS, UAN, and MFH.
  • To dig deeper into the stock's financial statements, go to DNA's page on browse-edgar?action=getcompany&CIK=0001830214.

DNA Valuation Summary

  • In comparison to the median Healthcare stock, DNA's EV/EBIT ratio is 108.14% lower, now standing at -0.7.
  • Over the past 21 months, DNA's EV/EBIT ratio has gone up 18.5.

Below are key valuation metrics over time for DNA.

Stock Date P/S P/B P/E EV/EBIT
DNA 2022-11-25 7.3 2.7 -1.1 -0.7
DNA 2022-11-23 7.3 2.7 -1.1 -0.7
DNA 2022-11-22 7.3 2.7 -1.1 -0.7
DNA 2022-11-21 7.7 2.8 -1.1 -0.8
DNA 2022-11-18 8.0 3.0 -1.2 -0.8
DNA 2022-11-17 7.9 2.9 -1.2 -0.8

DNA Stock Price Chart Interactive Chart >

Price chart for DNA

DNA Price/Volume Stats

Current price $1.85 52-week high $12.48
Prev. close $1.84 52-week low $1.81
Day low $1.84 Volume 19,159,600
Day high $1.95 Avg. volume 22,276,307
50-day MA $2.66 Dividend yield N/A
200-day MA $3.07 Market Cap 3.59B

Ginkgo Bioworks Holdings, Inc. (DNA) Company Bio

Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.

DNA Latest News Stream

Event/Time News Detail
Loading, please wait...

DNA Latest Social Stream

Loading social stream, please wait...

View Full DNA Social Stream

Latest DNA News From Around the Web

Below are the latest news stories about GINKGO BIOWORKS HOLDINGS INC that investors may wish to consider to help them evaluate DNA as an investment opportunity.

Cathie Wood Keeps Buying Ginkgo Bioworks (DNA) Stock

Ginkgo Bioworks has tumbled this week, but Cathie Wood is among the key buyers of DNA stock, picking up shares yesterday.

Chris MacDonald on InvestorPlace | November 18, 2022

Ginkgo Announces Public Offering of Class A Common Stock

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading platform for cell programing and biosecurity, today announced the sale of shares of its Class A common stock for gross proceeds of approximately $100 million to BTIG, LLC, as the underwriter in the registered public offering of those shares. In connection with this offering, Ginkgo has granted the underwriter a 30-day option to purchase up to an additional $15 million of shares of Class A common stock.

Yahoo | November 16, 2022

Ginkgo Bioworks Announces Proposed Public Offering of Class A Common Stock

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"),which is building the leading platform for cell programing and biosecurity, today announced that it intends to offer and sell $100 million of its Class A common stock in an underwritten public offering. As part of this offering, Ginkgo intends to grant the underwriter a 30-day option to purchase up to an additional $15 million of the shares of Class A common stock. All of the shares in the proposed offering are to be sold by Ginkgo.

Yahoo | November 15, 2022

Ginkgo Bioworks Reports Third Quarter 2022 Financial Results

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2022. The update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information, will be available at

Yahoo | November 14, 2022

Lygos and Ginkgo Bioworks Announce Partnership to Optimize Production of Biobased Specialty Chemicals

Lygos, Inc., a vertically integrated provider of sustainable specialty ingredients, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a multi-product research and development collaboration designed to optimize and scale production of sustainable specialty ingredients that can replace toxic petrochemistry, reclaim local manufacturing, and advance industrial bio-innovation.

Yahoo | November 11, 2022

Read More 'DNA' Stories Here

DNA Price Returns

1-mo -32.23%
3-mo -32.48%
6-mo -49.45%
1-year -84.41%
3-year N/A
5-year N/A
YTD -77.74%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.591 seconds.